A Boston-based biotech that rebuilt itself in 2025 around telitacicept, a dual BAFF/APRIL inhibitor licensed from RemeGen, now in global Phase III trials in myasthenia gravis and Sjögren's disease with the first readout due in 2027.
A Boston-based biotech that rebuilt itself in 2025 around telitacicept, a dual BAFF/APRIL inhibitor licensed from RemeGen, now in global Phase III trials in myasthenia gravis and Sjögren's disease with the first readout due in 2027.